Immune Response News and Research

RSS

Modified TB vaccine could help treat non-muscle invasive bladder cancer

A modified tuberculosis (TB) vaccine developed at Texas Biomed could help treat a form of bladder cancer, called non-muscle invasive bladder cancer, without strong side effects.

22 Aug 2022

“Drug factory” implants show promise in eradicating mesothelioma tumors

Rice University and Baylor College of Medicine researchers have shown they can eradicate advanced-stage mesothelioma tumors in mice in just a few days with a treatment combining Rice's cytokine "drug factory" implants and a checkpoint inhibitor drug.

22 Aug 2022

Human antibody responses to SARS-CoV-2 infection after two years

Scientists describe a protocol to evaluate antibody response dynamics up to two years following SARS-CoV-2 infection.

21 Aug 2022

New discovery helps explain the dynamics underlying liver damage in type 2 diabetes and obesity

When fat accumulates in the liver, the immune system may assault the organ. A new study from Weill Cornell Medicine researchers identifies the molecule that trips these defenses, a discovery that helps to explain the dynamics underlying liver damage that can accompany type 2 diabetes and obesity.

19 Aug 2022

Researchers harness plasma-produced gas to activate plant immunity against wide-spread diseases

The flash of lightning and the dance of auroras contain a fourth state of matter known as plasma, which researchers have harnessed to produce a gas that may activate plant immunity against wide-spread diseases.

19 Aug 2022

Researchers report the effects of a common Japanese herbal remedy on colitis

Zhengzheng Shi and colleagues at the RIKEN Center for Integrative Medical Sciences (IMS) in Japan report the effects of a common herbal remedy on colitis, one of two conditions that comprise inflammatory bowel disease (IBD).

18 Aug 2022

The impact of the P681H spike mutation in the SARS-CoV-2 Alpha variant

Researchers demonstrated the relevance of the P681H spike mutation in the SARS-CoV-2 Alpha variant.

17 Aug 2022

LSHTM expert comment: UK's MHRA approves bivalent COVID-19 vaccine

The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has approved a booster vaccine made by Moderna which targets two COVID-19 variants, known as a bivalent vaccine. Following clinical trial data that showed it triggers a strong immune response against both strains, the vaccine was found to meet the UK regulator's standards for safety, quality and effectiveness. Vaccine expert, Professor Beate Kampmann reacts to this announcement.

16 Aug 2022

Comparison of seroconversion rates and antibody responses in children across the three SARS-CoV-2 waves in Melbourne, Australia

Researchers evaluated antibody responses to SARS-CoV-2 variants in children.

16 Aug 2022

Next generation mRNA vaccines exhibit excellent protective and therapeutic effects

Researchers around the world have been working for years on developing vaccines against different types of cancer, but without much success. Now, Tufts School of Engineering researchers think they have found one that does work. They have devised a method of targeting cancer in mice with a vaccine that is so strong and precise, it eliminates tumors and even prevents their recurrence.

16 Aug 2022

Intestinal tissue-resident lymphocytes regulate their activity depending on glucose availability

A new study led by Marc Veldhoen, group leader at the Instituto de Medicina Molecular João Lobo Antunes (iMM; Portugal) and Associate Professor at Faculdade de Medicina de Lisboa (FMUL) and published today in the scientific journal PNAS (Proceedings of the National Academy of Sciences of the United States of America) discovered that white blood cells that reside in the intestines, a specific group of immune cells called tissue-resident lymphocytes, use sugar as an energy source and have a faster metabolism than lymphocytes that circulate in the blood.

15 Aug 2022

MHRA approves first bivalent COVID-19 booster vaccine

An updated version of the COVID-19 vaccine made by Moderna that targets two coronavirus variants (known as a "bivalent" vaccine) has today been approved for adult booster doses by the Medicines and Healthcare products Regulatory Agency (MHRA) after it was found to meet the UK regulator's standards of safety, quality and effectiveness.

15 Aug 2022